Genetic and Epigenetic Determinants of Aggressiveness in Cribriform Carcinoma of the Prostate.

Mol Cancer Res
Authors
Keywords
Abstract

Among prostate cancers containing Gleason pattern 4, cribriform morphology is associated with unfavorable clinicopathologic factors, but its genetic features and association with long-term outcomes are incompletely understood. In this study, genetic, transcriptional, and epigenetic features of invasive cribriform carcinoma (ICC) tumors were compared with non-cribriform Gleason 4 (NC4) in The Cancer Genome Atlas (TCGA) cohort. ICC ( = 164) had distinctive molecular features when compared with NC4 ( = 102). These include: (i) increased somatic copy number variations (SCNV), specifically deletions at 6q, 8p and 10q, which encompassed and losses and gains at 3q; (ii) increased and ; (iii) enrichment for and pathways by gene expression; and (iv) increased methylation of selected genes. In addition, when compared with the metastatic prostate cancer, ICC clustered more closely to metastatic prostate cancer than NC4. Validation in clinical cohorts and genomically annotated murine models confirmed the association with ( = 38) and ( = 818). The association of ICC with lethal disease was evaluated in the Health Professionals Follow-up Study (HPFS) and Physicians' Health Study (PHS) prospective prostate cancer cohorts (median follow-up, 13.4 years; = 818). Patients with ICC were more likely to develop lethal cancer [HR, 1.62; 95% confidence interval (CI), 1.05-2.49], independent from Gleason score (GS). IMPLICATIONS: ICC has a distinct molecular phenotype that resembles metastatic prostate cancer and is associated with progression to lethal disease.

Year of Publication
2019
Journal
Mol Cancer Res
Volume
17
Issue
2
Pages
446-456
Date Published
2019 Feb
ISSN
1557-3125
DOI
10.1158/1541-7786.MCR-18-0440
PubMed ID
30333152
PubMed Central ID
PMC6359952
Links
Grant list
P50 CA090381 / CA / NCI NIH HHS / United States
R01 CA187918 / CA / NCI NIH HHS / United States
U01 CA167552 / CA / NCI NIH HHS / United States
R37 CA215040 / CA / NCI NIH HHS / United States
P30 CA008748 / CA / NCI NIH HHS / United States
R01 CA131945 / CA / NCI NIH HHS / United States
K08 CA187417 / CA / NCI NIH HHS / United States
P50 CA211024 / CA / NCI NIH HHS / United States
UM1 CA167552 / CA / NCI NIH HHS / United States